Compounds and therapies for the prevention of vascular and non-vascular pathologies
Patent 6117911 Issued on September 12, 2000. Estimated Expiration Date: April 9, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/648, Two aryl rings or aryl ring systems bonded directly to the same acyclic carbon564/317Oxygen or sulfur is bonded directly to the carbon and is part of the chain
The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.
Other References
"Schering/Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer `Similar` to Taxoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16 (Oct. 23, 1995)
Agarwal, A.K., et al., "Estrogen Receptor-Binding Affinity of Tamoxifen Analogs with Various Side Chains and Their Biologic Profile in Immature Rat Uterus", Steroids, 56, 486-489 (Sep. 1991)
Burton, T.M., "Lilly Osteoporosis Treatment Shows Promise", The Wall Street Journal, p. A3, A6 (Jun. 6, 1997)
Butta, A., et al., "Induction of Transforming Growth Factor ଲ1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment", Cancer Research, 52, 4261-4164 (Aug. 1, 1992)
Chandler, et al., "Pyrrolidino-4-iodotamoxifen and 4-Iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer", Cancer Research, 51, 5851-5858 (Nov. 1, 1991)
Chandraesekar, B., et al., "Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor ଲ mRNA and Protein Expression", Journal of Autoimunity, 8, 381-393 (1995)
Colletta, A.A., et al., "Anti-Oestrogens Induce the Secretion of Active Transforming Growth Factor Beta from Human Fetal Fibroblasts", Br. J. Cancer, 62, 405-409 (1990)
Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastic Breast Cancer", Cancer Research, 55, 1070-1074 (Mar. 1, 1995)
Cunningham, A., et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", Mutation Research, 349, 85-94 (1996)
Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", Carcinogenesis, 16, 539-545 (1995)
Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: The Treatment of Cancer: Beyond Chemotherapy, Conference Documentation, The Gloucester Hotel, London, 7 p. (Mar. 13-14, 1995)
Dragan, Y.P., et al., "Comparison of the Effects of Tamoxifen and Toremifene on Liver and Kidney Tumor Promotion in Female Rats", Carcinogenesis, 16, 2733-2741 (1995)
Grainger, et al., "The Serum Concentration of Active Transforming Growth Factor (beta) is Severly Depressed in Advanced Atherosclerosis", Nature Medicine, 1, 74-80 (Jan. 1995)
Hardcastle, I.R., et al., "Homologs of Idoxifene: Variation of Estrogen Receptor Binding and Calmodulin Antagonism with Chain Length", J. Med. Chem., 39, 999-1004 (1996)
Hayes, D.F., et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566 (Oct. 1995)
Jones, R.H.V., et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens ଲL Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicylic Acid", Exp. Eye Res., 57, 783-790 (1993)
Kellen, J.A., et al., "The Effect of Toremifene on the Expression of Genes in a Rat Mammary Adenocarcinoma", In Vivo, 10, 511-514 (1996)
Knabbe, C., et al., "Induction of Transforming Growth Factor ଲ by the Antiestrogens Droloxifene, Tamoxifen, and Toreifene in MCF-7 Cells", Am. J. Clin. Oncol. (CCT), 14, S15-S20 (1991)
Kopp, A., et al., "Transforming Growth Factor 댢 (TGF-댢) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen", Cancer Research, 55, 4512-4515 (Oct. 15, 1995)
Kuramochi, H., "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", J. Med. Chem., 39, 2877-2886 (1996)
Loser, R., et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Eur. J. Cancer Clin. Oncol., 21, 985-990 (1985)
Magarian, R.A., et al., "Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review", Current Medicinal Chemistry, 1, 61-104 (1994)
McCague, R., et al., "An Efficient, Large-Scale Synthesis of Idoxifene {(E)-1-[4 -[2-(N-pyrrolidino)ethoxy]phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene}", Organic Preparations and Procedures Int., 26, 343-346 (1994)
McCague, R., et al., "Synthesis of 4-Stannylated Tamoxifen Analogues: Useful Precursors to Radiolabelled Idoxifene and Aziridinyl 4-Iodotamoxifen", Journal of Labelled Compounds and Radiopharmaceuticals, 34, 297-302 (1994)
Moorthy, B., et al., "Tamoxifen Metabolic Activation: Comparison of DNA Adducts Formed by Microsomal and Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Adducts Formed in Vivo", Cancer Research, 56, 53-57 (Jan. 1, 1996)
Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Importance of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 421-428 (1991)
Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078 (1985)
Pennisi, E., "Drug's Link to Genes Reveals Estrogen's Many Sides", Science, 273, 1171 (Aug. 30, 1996)
Potter, G.A., et al., "A Mechanism Hypothesis for DNA Adduct Formation Following Hepatic Oxidative Metabolism.", Carcinogensis, 15, 439-442 (1994)
Sargent, L.M., et al., "Induction of Hepatic Aneuploidy in Vivo by Tamoxifen, Toremifene and Idoxifene in Female Sprague-Dawley Rats", Carcinogenesis, 17, 1051-1056 (1996)
Sudo, K., et al., "Antiestrogen-Binding Sites Distinct from the Estrogen Receptor: Subcellular Localization, Ligand Specificity, and Distribution in Tissues of the Rat", Endocrinology, 112, 425-434 (1983)
Testart, J., et al., "The Action of Anti-Inflammatory Drugs to the Fertility of Female Rats with Intrauterine Contraceptive Devices", J. Reprod. Fert., 63, 257-261 (1981)
Wiseman, L.R., et al., "Toremifene--A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Advanced Breast Cancer", Drugs, 54, 141-160 (Jul. 1997)
Yang, N.N., et al., "Estrogen Receptor: One Transcription Factor, Two Genomic Pathways", Calcified Tissue Intl., 54, 342 (1994)
Yang, N.N., et al., "Identification of an Estrogen Response Element Activated by Metabolites of 17ଲ-Estradiol and Raloxifene", Science, 273, 1222-1225 (Oct. 30, 1996)
Young, H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET in the Evaluation of a Novel Antioestrogen for Cancer Therapy", Nucl. Med. Biol., 22, 405-411 (1995)
Charlier, et al., "Tamoxifen in the Treatment of Breast Cancer", J. Gynecol. Obstet Biol. Reprod. (Paris), 23, 751-756 (1994). Abstract only
Grainger, D.J., et al., "A Pivotal Role for TGF-ଲ in Atherogenesis?", Biol. Rev., 70, 571-596 (1995)
Grainger, D.J., et al., "Release and Activation of Platelet Latent TFG-Beta in Blood Clots During Dissolution with Plasmin", Nature Medicine, 1, 932-937 (1995
April 9, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
